Home › Compare › CAIHF vs ABBV
CAIHF yields 714.29% · ABBV yields 3.06%● Live data
📍 CAIHF pulled ahead of the other in Year 1
Combined, CAIHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CAIHF + ABBV for your $10,000?
Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment manufactures and sells CTC premix and CTC hydrochloride products, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brands. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of carburetors and automotive parts for automobile and motorcycle manufacturers. The company was incorporated in 1987 and is based in Central, Hong Kong. Chia Tai Enterprises International Limited is a subsidiary of Charoen Pokphand Foods Public Company Limited.
Full CAIHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.